Australia markets closed

Profound Medical Corp. (PROF)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
7.73-0.79 (-9.27%)
At close: 04:00PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 207.04M
Enterprise value 188.76M
Trailing P/E 73.68
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)25.07
Price/book (mrq)6.68
Enterprise value/revenue 26.22
Enterprise value/EBITDA -5.75

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-38.39%
S&P500 52-week change 326.43%
52-week high 315.49
52-week low 37.11
50-day moving average 38.14
200-day moving average 38.92

Share statistics

Avg vol (3-month) 333.33k
Avg vol (10-day) 324.37k
Shares outstanding 524.43M
Implied shares outstanding 624.45M
Float 821.68M
% held by insiders 18.71%
% held by institutions 141.03%
Shares short (15 Apr 2024) 4313.73k
Short ratio (15 Apr 2024) 411.97
Short % of float (15 Apr 2024) 4N/A
Short % of shares outstanding (15 Apr 2024) 41.28%
Shares short (prior month 15 Mar 2024) 4320.72k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 316 Oct 2019
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)-391.73%

Management effectiveness

Return on assets (ttm)-30.83%
Return on equity (ttm)-59.26%

Income statement

Revenue (ttm)7.25M
Revenue per share (ttm)0.33
Quarterly revenue growth (yoy)2.70%
Gross profit (ttm)N/A
EBITDA -28.49M
Net income avi to common (ttm)-28.03M
Diluted EPS (ttm)-1.35
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)41.18M
Total cash per share (mrq)1.73
Total debt (mrq)7.24M
Total debt/equity (mrq)15.78%
Current ratio (mrq)5.41
Book value per share (mrq)1.92

Cash flow statement

Operating cash flow (ttm)-21.57M
Levered free cash flow (ttm)-12.64M